Last updated 3 days ago

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

153 patients around the world

Available in Argentina, Spain

Bristol-Myers Squibb

1Research sites

153Patients around the world

This study is for people with

Psoriasis

Plaque psoriasis

To 18 Years

All Gender

: Males and females aged 12 to <18 years for Cohort 1. Males and females aged 4 to <12 years for Cohort 2.
Plaque psoriasis for at least 6 months
Moderate to severe disease
Candidate for phototherapy or systemic therapy
Must have completed the Week 52 treatment period in Part A or B for long-term extension (LTE) period

: Participants weighing ≤ 30.0 kg at screening for Cohort 1 (age 12 to < 18 years), Part A and Part B. Participants weighing ≤ 13.0 kg at screening for Cohort 2 (age 4 to < 12 years), Part A and Part B.
Other forms of psoriasis
History of recent infection
Prior exposure to deucravacitinib (BMS-986165) or active comparator
Evidence of active TB for LTE period

Psoriahue Medicina Interdisciplinaria - CABA, Buenos Aires

Recruiting

Bulnes 1937, CABA, Buenos Aires

SponsorBristol-Myers Squibb

Study typeInterventional

Conditions

Plaque psoriasis

Requirements

To 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT04772079